Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Mission Therapeutics
Mission Therapeutics
Activities:
Manufacturing
Drug Delivery
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
N4 Pharma and SRI to target and treat previously unreachable human cells
The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Mission Therapeutics announces FDA approval for Phase II trial in acute kidney injury
Mission gains clearance from US FDA for Phase II trial of MTX562 after it receives official approval of its Investigational New Drug (IND) application
Research & Development
Mission paper outlines potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson’s
The research was the result of collaborative work between Cambridge University, Harvard Medical School and Mission Therapeutics
Finance
Mission appoints Dr Suhail Nurbhai CMO
Dr Nurbhai has more than 25 years of experience in the strategic and operational leadership of all phases of clinical research and development at companies across Europe and the US
Ingredients
Mission raises $15m and expands relationship with Pfizer
The new capital will support the development of Mission's deubiquitylating enzymes (DUB) platform, as well as growth of its pipeline of DUB inhibitor programmes
Drug Delivery
Dr Nick Edmunds appointed to VP, Head of DUB Discovery
Recruitment
Mission Therapeutics strengthens clinical development team
Recruitment
Mission Therapeutics appoints Dr Bobby Soni to board
Subscribe now